Cell lines

Oral Candida species and human buccal epithelial cells

Preparation method

The solubility of this compound in DMSO is >30.5 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 ℃ for several months.

Reacting condition

1 hr

Applications

The minimal inhibitory concentrations (μg/mL) of Nystatin for C. albicans, C. tropicalis, C. krusei, C. parapsilosis, C. glabrata and C. guilliermondii in RPMI broth were 0.78 ~ 1.56, 1.56 ~ 3.12, 3.12, 1.56 ~ 3.12, 0.78 ~ 1.56 and 0.39 ~ 0.78, respectively. Compared with the control group, Nystatin significantly reduced adhesion of 6 Candida species to buccal epithelial cells. However, the adhesion of C. albicans isolates was least affected by Nystatin treatment, which was significantly different from that of the non-albicans species.

Animal models

Aspergillus-infected, neutropenic mice

Dosage form

2, 4, 6 and 8 mg/kg/day; i.v.

Applications

At a dose as low as 2 mg/kg/day, Liposomal Nystatin significantly protected neutropenic mice from Aspergillus-induced death compared to either the no-treatment, the saline or the empty-liposome group. Liposomal Nystatin-treated mice showed no evidence of Aspergillus infection either at day 5 in all of the treatment groups or at day 52 in the 8 mg/kg/day liposomal-Nystatin treatment group.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Nystatin (Fungicidin) is a polyene antifungal antibiotic [1].
Antifungal antibiotic is a pharmaceutical fungicide used to treat and prevent mycoses.
Nystatin is a polyene antifungal antibiotic that is effective against yeast and mycoplasma [1]. In liquid media, Nystatin inhibited C. albicans at concentrations of 5-20 U/ml[2].
In a 200 clinical isolates, which comprised of 113 Candida albicans, 54 Candida glabrata, 11 Candida parapsilosis, 11 Candida tropicalis and 11 Candida krusei. Nystatin exhibited MIC90 value of 4 mg/L against C. albicans isolates and all non-albicans Candida species tested. The results confirmed C. Albicans was most frequently susceptible and Nystatin could be used to treat vulvovaginal candidiasis caused by non-albicans Candida species. Nystatin would be an important choice for women affected by non-albicans Candida species which present higher resistance to the imidazole-based treatments [3].
References:
[1]. Childs AJ. Effect of Nystatin on Growth of Candida albicans During Antibiotic Therapy. Br Med J, 1956, 1(4968): 660-662.
[2]. Stewart GT. Laboratory and Clinical Studies with Nystatin in Post-antibiotic Mycotic Infections. Br Med J, 1956, 1(4968): 658-660.
[3]. Choukri F, Benderdouche M, Sednaoui P. In vitro susceptibility profile of 200 recent clinical isolates of Candida spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents. J Mycol Med, 2014, 24(4): 303-307.